Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 11, 2010, Pages 1457-1470

  Uckun, Fatih M ^a,b   Qazi, Sanjive ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c GUSTAVUS ADOLPHUS COLLEGE   (United States)

Author keywords

Bruton's tyrosine kinase; graft versus host disease; inflammatory disorders; leukemia; lymphoma; rational drug design; thromboembolism

Indexed keywords

2 CYANO N (2,5 DIBROMOPHENYL) 3 HYDROXYCROTONAMIDE; AVL 101; AVL 291; BRUTON TYROSINE KINASE; DASATINIB; PCI 32765; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; INFLAMMATORY DISEASE; LEUKEMIA; LYMPHOMA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; UPREGULATION;

ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; LEUKEMIA; LYMPHOMA; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 77958497298     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.517750     Document Type: Review

References (146)

1. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-34
2. Dunn D. Mining the human 'kinome. Drug Discov Today 2002;7:1121-3
3. Traxler P. Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin Ther Targets 2003;7:215-25
4. Tibes R, Trent J, Kurzrock R Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 2005;45:357-63
5. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-7
6. Arora A, and Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-9
7. Sudbeck EA, Liu XP, Narla RK, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999;5:1569-82
8. Mahajan S, Ghosh S, Sudbeck EA, Uckun FM. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl) propenamide]. J Biol Chem 1999;274:9587-93
9. Qiu Y, Kung HJ. Signaling network of the Btk family kinases. Oncogene 2000;19:5651-5
10. Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 2009;228:132-48
11. Uckun FM. Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem Pharmacol 1998;56:683-99
12. Takesono A, Finkelstein, LD, Schwartzberg PL. Beyond calcium: new signaling pathways for TEC family kinases. J Cell Sci 2002;115:3039-48
13. Schwartzberg PL, Finkelstein LD, Readinger JA. TEC-family kinases: regulators of T-helper-cell differentiation. Nat Rev Immunol 2005;5:284-95
14. Finkelstein LD, Schwartzberg PL. TEC kinases: shaping T-cell activation through actin. Trends Cell Biol 2004;14:443-51
15. Bence K, Ma W, Kozasa T, Huang XY. Direct stimulation of Bruton's tyrosine kinase by G(q)-protein alpha-subunit. Nature 1997;389:296-9
16. Fukuda M, Kojima T, Kabayama H, Mikoshiba K. Mutation of the pleckstrin homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity. J Biol Chem 1996;271(48):30303-6
17. Kojima T, Fukuda M, Watanabe Y, et al. Characterization of the pleckstrin homology domain of Btk as an inositol polyphosphate and phosphoinositide binding domain. Biochem Biophys Res Commun 1997;236:333-9
18. Salim K, Bottomley MJ, Querfurth E, et al. Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. Embo J 1996;15:6241-50
19. Langhans-Rajasekaran SA, Wan Y, Huang XY. Activation of Tsk and Btk tyrosine kinases by G protein beta gamma subunits. Proc Natl Acad Sci USA 1995;92:8601-5
20. Tsukada S, Simon MI, Witte ON, Katz A. Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. Proc Natl Acad Sci USA 1994;91:11256-60
21. Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase cbeta-deficient mice. Science 1996;273:788-91
22. Saharinen P, Ekman N, Sarvas K, et al. The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta. Blood 1997;90:4341-53
23. Crosby D, Poole AW. Interaction of Bruton's tyrosine kinase and protein kinase Ctheta in platelets. Cross-talk between tyrosine and serine/threonine kinases. J Biol Chem 2002;277:9958-65
24. Crosby D, Poole AW. Physical and functional interaction between PKCdelta and Fyn tyrosine kinase in human platelets. J Biol Chem 2003;278:24533-41
25. Yao L, Janmey P, Frigeri LG, et al. Pleckstrin homology domains interact with filamentous actin. J Biol Chem 1999;274:19752-61
26. Rawlings DJ, Witte ON. Bruton's tyrosine kinase is a key regulator in B-cell development. Immunol Rev 1994;138:105-19
27. Uckun FM, Waddick KG, Mahajan S, et al. BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Science 1996;273:1096-100
28. Kersseboom R, Ta VB, Zijlstra AJ, et al. Bruton's tyrosine kinase and SLP-65 regulate pre-B cell differentiation and the induction of Ig light chain gene rearrangement. J Immunol 2006;176:4543-52
29. Irish JM, Czerwinski DK, Nolan GP, Levy R Altered B cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor infiltrating non-malignant B cells. Blood 2006;108(9):3135-42
30. Rajaiya J, Nixon JC, Ayers N, et al. Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I. Mol Cell Biol 2006;26:4758-68
31. Lindvall JM, Blomberg KE, Wennborg A, Smith CI. Differential expression and molecular characterisation of Lmo7, Myo1e, Sash1, and Mcoln2 genes in Btk-defective B-cells. Cell Immunol 2005;235:46-55
32. Bajpai UD, Zhang K, Teutsch M, et al. Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med 2000;191:1735-44
33. EgloffAM, Desiderio S. Identification of phosphorylation sites for Bruton's tyrosine kinase within the transcriptional regulator BAP/TFII-I. J Biol Chem 2001;276:27806-15
34. Perez Jurado LA, Wang, YK, Peoples R, et al. A duplicated gene in the breakpoint regions of the 7q11.23 Williams-Beuren syndrome deletion encodes the initiator binding protein TFII-I and BAP-135, a phosphorylation target of BTK. Hum Mol Genet 1998;7:325-34
35. Yang W, Desiderio S. BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement. Proc Natl Acad Sci USA 1997;94:604-9
36. Peters KL, Smithgall TE. Tyrosine phosphorylation enhances the SH2 domain-binding activity of Bcr and inhibits Bcr interaction with 14-3-3 proteins. Cell Signal 1999;11:507-14
37. Mahajan S, Vassilev A, Sun, N, et al. Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J Biol Chem 2001;276:31216-28
38. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005;103:1551-60
39. Fulda S, Debatin KM. Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets 2004;4:569-76
40. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003;22:7414-30
41. Vassilev A, Ozer Z, Navara C, et al. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 1999;274:1646-56
42. Feldhahn N, Klein F, Mooster JL, et al. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med 2005;201:1837-52
43. Glassford J, Soeiro I, Skarell SM, et al. BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells. Oncogene 2003;22:2248-59
44. Bajpai UD, Zhang K, Teutsch M, et al. Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med 2000;191:1735-44
45. Petro JB, Khan WN. Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. J Biol Chem 2001;276:1715-9
46. Spiekermann K, Pau M, Schwab R, et al. Constitutive activation of STAT3 and STAT5 is induced by leukemic furion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002;30:262-71
47. Nakayama J, Yamamoto M, Hayashi K, et al. BLNK suppresses pre-B cell leukemogenesis through inhibition of JAK3. Blood 2009;113:1483-92
48. Nagy ZS, Rui H, Stepkowski SM, et al. A preferential role for STAT5, not constitutively active STAT3, in promoting survival of a human lymphoid tumor. J Immunol 2006;177:5032-40
49. Debierre-Grockiego F. Anti-apoptotic role of STAT5 in hematopoietic cells and in the pathogenesis of malignancies. Apoptosis 2004;9:717-28
50. Lanvin O, Gouilleux F, Mullie C, et al. Interleukin 7 induces apoptosis of 697 pre-B cells expressing dominant negative forms of STAT5: evidence for caspase-dependent and-independent mechanisms. Oncogene 2004;23:3040-7
51. Mowafi F, Cagigi A, Matskova L, et al. Chemokine CXCL12 enhances proliferation in pre-B ALL via STAT5 activation. Pediatr Blood Cancer 2008;50:812-7
52. Baskiewicz-Masiuk M, Machalinski B. The influence of STAT5 antisense oligonucleotides on the proliferation and apoptosis of selected human leukemic cell lines. Cell Prolif 2003;36:265-78
53. Sonoyama J, Matsumura I, Ezoe S, et al. Functional coorperation among Ras, STAT5, and phosphatidylinositol 3-kinease is required for full oncogenic activities of BCR-ABL in K562 cells. J Biol Chem 2002;277:8076-82
54. Baskiewicz-Masiuk M, Machalinski B. The role of the STAT5 proteins in the proliferation and apoptosis of CML and AML cells. Eur J Hematol 2004;272:420-9
55. Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia 1-down regulation. Mol Pharmacol 2007;72:788-95
56. Nam S, Williams A, Vultur A, et al. Dasatinib (BMS-354825) inhibits STAT5 signaling associated with apoptosis in chronic myelogeneous leukemia cells. Mol Cancer Ther 2007;6:1400-5
57. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005;7:591-600
58. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-1300
59. Hsieh AC, Bo R, Manola J, et al. A library of siRNA duplexes targeting phosphoinositide 3-kinease pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acid Res 2004;32:893-901
60. Avellino R, Romano S, Parasole R, et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005;106:1400-6
61. Cisterne A, Thien M, Hewson J, et al. Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 2009;113:3297-306
62. Verschuren MC, Kraakman ME, Mensink RG, et al. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol 1993;23:3109-14
63. Martinez N, Camacho FI, Ruiz-Ballesteros E, et al. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res 2004;10:6796-806
64. Ortolano S, Hwang IY, Han SB, Kehrl JH. Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol 2006;36:1285-95
65. Ritis K, Speletas M, Tsironidou V, et al. Absence of Bruton's tyrosine kinase (Btk) mutations in patients with acute myeloid leukaemia. Br J Hematol 1998;102:1241-8
66. Kaukonen J, Lahtinen I, Laine S, et al. BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias. Br J Hematol 1996;94:455-60
67. Tu T, Thotala D, Geng L, et al. Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium. Cancer Res 2008;68:2861-9
68. Davis RE, Ngo VN, Lenz G, et al. Chronic active B cell receptor signaling in diffuse large B cell lymphoma. Nature 2010;463:88-92
69. Uckun FM, Zheng Y, Cetkovic-Cvrlje M, et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res 2002;8:1224-33
70. Thomas ED. Stem cell transplantation: past, present and future. Arch Immunol Ther Exp (Warsz) 1997;45:1-5
71. Trigg ME. Bone marrow transplantation for treatment of leukemia in children. Pediatr Clin North Am 1988;35:933-48
72. Butturini A, Gale RP. Allogeneic bone marrow transplantation for leukemia. Curr Opin Hematol 1994;1:402-5
73. Henslee-Downey PJ. Mismatched bone marrow transplantation. Curr Opin Oncol 1995;7:115-21
74. Porter DL, Collins RH, Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant 1999;5:253-61
75. Orchard PJ, Miller JS, McGlennen R, et al. Graft-versus-leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia. Bone MarrowTransplant 1998;22:201-3
76. Slavin S, Nagler A, Shapira M, et al. Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases. Crit Rev Oncol Hematol 2001;39:25-9
77. Spitzer TR, McAfee S, Sackstein R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000;6:309-20
78. Cetkovic-Cvrlje M, Uckun FM. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br J Haematol 2004;126:821-7
79. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004;30:95-108
80. Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist 2005;10:72-9
81. Ameriso SF. The treatment of cerebrovascular disorders with anticoagulants and platelet aggregation inhibitors. RevNeurol 1999;29:1285-90
82. Gibbins JM, Okuma M, Farndale R, et al. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett 1997;413:255-9
83. Moroi M, Jung SM. Platelet receptors for collagen. Thromb Haemost 1997;78:439-44
84. Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem 1997;272:23528-31
85. Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. CurrBiol 1998;8:1137-40
86. Oda A, Ikeda Y, Ochs HD, et al. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/TEC kinases in platelets induced by collagen binding or CD32 cross-linking. Blood 2000;95:1663-70
87. Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 2004;117:3415-25
88. Watson S. Collagen receptor signalling in platelets:extending the role of the ITAM. Immunol Today 1998;19:260-4
89. Gross BS, Wilde JI, Quek L, et al. Regulation and function of WASp in platelets by the collagen receptor, glycoprotein VI. Blood 1999;94:4166-76
90. Tibbles H, Vassilev A, Uckun FM. A dual function anti-leukemic agent with anti-thrombotic activity. Leuk Lymphoma 2002;43:1121-7
91. Uckun FM, VassilevAO, Bartell S, et al. The Anti-leukemic Bruton's tyrosine kinase inhibitor LFM-A13 prevents fatal thromboembolism. Leuk Lymphoma 2003;44:1569-77
92. Tibbles HE, Samuel P, Erbeck D, et al. In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F. Arzneimittelforschung Drug Res 2004;54:330-9
93. Ott N, Ramsay NK, Priest JR, et al. Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1988;10:191-5
94. Conley ME, Broides A, Hernandez-Trujillo V, et al. Genetic analysis of patients with defects in early B-cell development. Immunol Rev 2005;203:216-34
95. Lindvall JM, Blomberg KE, Valiaho J, et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005;203:200-15
96. Verbruggen G, De Backer S, Deforce D, et al. X linked agammaglobulinaemia and rheumatoid arthritis. Ann Rheum Dis 2005;64:1075-8
97. Liljeroos M, Vuolteenaho R, Morath S, et al. Bruton's tyrosine kinase together with PI 3-kinase are part of Toll-like receptor 2 multiprotein complex and mediate LTA induced Toll-like receptor 2 responses in macrophages. Cell Signal 2006;19:625-33
98. Horwood NJ, Page TH, McDaid JP, et al. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 2006;176:3635-41
99. Horwood NJ, Mahon T, McDaid JP, et al. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor {alpha} production. J Exp Med 2003;197:1603-11
100. Ortolano S, Hwang IY, Han SB, Kehrl JH. Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol 2006;36:1285-95
101. Gilbert C, Levasseur S, Desaulniers P, et al. Chemotactic factor-induced recruitment and activation of TEC family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor. J Immunol 2003;170:5235-43
102. Fernandes MJ, Lachance G, Pare G, et al. Signaling through CD16b in human neutrophils involves the TEC family of tyrosine kinases. J Leukoc Biol 2005;78:524-32
103. Matsuo K, Hotokezaka H, Ohara N, et al. Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules. Microbiol Immunol 2006;50:337-47
104. Doyle SL, Jefferies CA, O'Neill LA. Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide. J Biol Chem 2005;280:23496-501
105. Olsson S, Sundler R Different roles for non-receptor tyrosine kinases in arachidonate release induced by zymosan and Staphylococcus aureus in macrophages. J Inflamm (Lond) 2006;3:8-15
106. MedicineNet.com Asthma information. Available from: http://www. medicinenet.com/asthma/page2.htm
107. American Lung Association. Epidemiology & statistics Unit, R. a. P. S. Trends in Asthma Morbidity and Mortality; May 2005
108. Popescu, FD. Antisense-and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med 2005;9:840-53
109. Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett 2002;527:274-8
110. Uckun FM. Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases. Cell Cycle 2007;6:3021-6
111. Kim YJ, Sekiya F, Poulin B, et al. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol 2004;24:9986-99
112. Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett 2002;527:274-8
113. Martino A, Holmes JH, Lord JD, et al. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J Immunol 2001;166:1723-9
114. Fernandez deMattos S, Essafi A, Soeiro I, et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol. 2004, 24:10058-71
115. Uckun FM, Zheng Y, Ghosh S. "BTK inhibitors and methods for their identification and use." US6221900; 2001
116. Uckun FM, Zheng Y, Ghosh S. "BTK inhibitors and methods for their identification and use." US6160010; 2000
117. Uckun FM, Zheng Y, Ghosh S. "BTK inhibitors and methods for their identification and use." US6365626; 2002
118. Uckun FM, Zheng Y, Ghosh S. "BTK inhibitors and methods for their identification and use." US6303652; 2001
119. Uckun FM, Zheng Y, Ghosh S. "BTK inhibitors and methods for their identification and use." US6294575; 2001
120. Uckun FM, Malaviya R "BTK inhibitors and methods for their identification and use." US6753348; 2004
121. Uckun FM, Zheng Y, Ghosh S. BTK Inhibitors and methods for their identification and use. EP1071658B1; 2004
122. Zhu Z. Intrabodies. US20100143371; 2010
123. Honigberg L. Inhibitors of Bruton's tyrosine kinase. US20100041677; 2010
124. Honigberg L, Verner E, Pan Z. Inhibitors of Bruton's tyrosine kinase. US20100022561; 2010
125. Honigberg L, Verner E, Pan Z. Inhibitors of Bruton's tyrosine kinase. US20100004270; 2010
126. Honigberg L, Verner E, Pan Z. Inhibitors of Bruton's tyrosine kinase. US20090191987; 2009
127. Honigberg L, Verner E, Pan Z. Inhibitors of Bruton's tyrosine kinase. US20080139582; 2008
128. Tripp M, Babish J, Bland J, et al. Substituted 1,3-Cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith. US20100137449; 2010
129. Kennedy-Smith J, Kondru RK, Loe BE, et al. Inhibitors of Bruton's tyrosine kinase. US20100099659; 2010
130. Jankowski OD, Palmer JT, Honigberg L. Inhibitors of tyrosine kinases and uses thereof. US20100035841; 2010
131. Johns RA, Su Q, Champion HC. HIMF nd BTK in pulmonary, cardiac, and inflammation disorders. US20100028355; 2010
132. Dewdney NJ, Lou Y, Sjogren E, et al. Inhibitors of Bruton's tyrosine kinase. US20100004231; 2010
133. Dewdney NJ, Kondru RK, Loe BE, et al. Inhibitors of Bruton's tyrosine kinase. US20090318448; 2009
134. Dewdney NJ, Kennedy-Smith J, Kondru RK, et al. Inhibitors of Bruton's tyrosine kinase. US20090306041; 2009
135. Dewdney NJ, Lou Y, Sjogren E, Soth M. Inhibitors of Bruton's tyrosine kinase. US20100016301; 2010
136. Barbosa A, Blomgren P, Currie K, et al. Pyridazinones and their use as BTK inhibitors. PCT/US2009064224; 2009
137. Blomgren P, Currie KS, Mitchell SA, Brittelli DR Heterocyclic amides as BTK inhibitors. PCT/US2009067547; 2009
138. Blomgren P, Currie KS, Mitchell SA, et al. Certain substituted amides, method of making and use as BTK inhibitors. PCT/US2009067575; 2009
139. Currie KS, Lee SH, Darrow JW, Blomgren PA. Pryrimidines derivatives and their use as kinase inhibitors. PCT/US2007078154; 2007
140. Barrish JC, Das J, Liu C, et al. Thiazolyl inhibitors of TEC family tyrosine kinases. PCT/US2001049430; 2001
141. Pan Z, Scheerens H, Li SJ, et al. Discovery of slective irreversible inhibitors of Bruton's tyrosine kinase. ChemMedChem 2007;2:58-61
142. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107:13075-80
143. Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr Opin Chem Biol 2010;14:1-6
144. Evans E, Tester R, Aslanian S, et al. A novel platform-based approach to silence oncoproteins using small molecule therapeutics-Application to Bruton's tyrosine kinase [abstract 3739]. Proc. AACR Symp. Denver, CO; 2009
145. Marcotte DJ, Liu YT, Arduini RM, et al. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci 2010;19:429-39
146. Mao C, Zhou M, Uckun FM. Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem 2001;276:41435-43